Skip to main content
Erschienen in: Pneumo News 5/2019

27.08.2019 | Pneumonie | cme fortbildung

Pneumokokken, Pertussis und Influenza

Empfohlene Impfungen bei Lungenkranken

verfasst von: Univ.-Prof. Dr. Florian Thalhammer, DTMH Hamburg

Erschienen in: Pneumo News | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Für Lungenkranke ist es wichtig, die Imfungen gegen Grippe, Pneumokokken und Keuchhusten wahrzunehmen, da diese die Morbidität und Mortalität bei invasiven Lungeninfektionen signifikant reduzieren. Eigentlich Grund genug, sich impfen zu lassen — zumindest theoretisch.
Literatur
1.
Zurück zum Zitat Ewig S, Höffken G, Kern WV et al. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention — Update 2016. Pneumologie. 2016 Mar;70(3):151–200CrossRefPubMed Ewig S, Höffken G, Kern WV et al. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention — Update 2016. Pneumologie. 2016 Mar;70(3):151–200CrossRefPubMed
2.
3.
Zurück zum Zitat Adler H, Nikolaou E, Gould K et al. Pneumococcal Colonization in Healthy Adult Research Participants in the Conjugate Vaccine Era, United Kingdom, 2010-2017. J Infect Dis. 2019;219(12):1989–1993CrossRefPubMedPubMedCentral Adler H, Nikolaou E, Gould K et al. Pneumococcal Colonization in Healthy Adult Research Participants in the Conjugate Vaccine Era, United Kingdom, 2010-2017. J Infect Dis. 2019;219(12):1989–1993CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Peterson JT, Stacey HL, MacNair JE et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(3):540–548CrossRefPubMed Peterson JT, Stacey HL, MacNair JE et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(3):540–548CrossRefPubMed
5.
Zurück zum Zitat Stacey HL, Rosen J, Peterson JT et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15(3):530–539CrossRefPubMed Stacey HL, Rosen J, Peterson JT et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15(3):530–539CrossRefPubMed
6.
Zurück zum Zitat Kolditz M, Schmitt J, Pletz MW, Tesch F. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ?60 years-a population-based retrospective cohort study. Clin Microbiol Infect. 2018;24(5):500–504CrossRefPubMed Kolditz M, Schmitt J, Pletz MW, Tesch F. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ?60 years-a population-based retrospective cohort study. Clin Microbiol Infect. 2018;24(5):500–504CrossRefPubMed
7.
Zurück zum Zitat Roca A, Bottomley C, Hill PC et al. Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage. Clin Infect Dis. 2012;55(6):816–24CrossRefPubMedPubMedCentral Roca A, Bottomley C, Hill PC et al. Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage. Clin Infect Dis. 2012;55(6):816–24CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010 Jan 1;201(1):32–41CrossRefPubMed Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010 Jan 1;201(1):32–41CrossRefPubMed
9.
Zurück zum Zitat van Deursen AMM, van Houten MA, Webber C et al. Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clin Infect Dis. 2017 Sep 1;65(5):787–795CrossRefPubMed van Deursen AMM, van Houten MA, Webber C et al. Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clin Infect Dis. 2017 Sep 1;65(5):787–795CrossRefPubMed
10.
Zurück zum Zitat Naucler P, Galanis I, Morfeldt E et al. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clin Infect Dis. 2017;65(11):1780–1789CrossRefPubMedPubMedCentral Naucler P, Galanis I, Morfeldt E et al. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clin Infect Dis. 2017;65(11):1780–1789CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Desmet S, Verhaegen J, Van Ranst M et al. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis. 2018;18(8):830–831CrossRefPubMed Desmet S, Verhaegen J, Van Ranst M et al. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis. 2018;18(8):830–831CrossRefPubMed
12.
Zurück zum Zitat Gessner BD, Sings HL, Jodar L. Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines. Lancet Infect Dis. 2019;19(7):692–693CrossRefPubMed Gessner BD, Sings HL, Jodar L. Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines. Lancet Infect Dis. 2019;19(7):692–693CrossRefPubMed
13.
Zurück zum Zitat Schroeder MR, Chancey ST, Thomas S et al. A Population-Based Assessment of the Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms. Clin Infect Dis. 2017;65(6):990–998CrossRefPubMedPubMedCentral Schroeder MR, Chancey ST, Thomas S et al. A Population-Based Assessment of the Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms. Clin Infect Dis. 2017;65(6):990–998CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.https://doi.org/10.1136/bmj.j2471CrossRefPubMed Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.https://​doi.​org/​10.​1136/​bmj.​j2471CrossRefPubMed
16.
Zurück zum Zitat van Belkum A, Verkaik NJ, de Vogel CP et al. Reclassification of Staphylococcus aureus nasal carriage types. J Infect Dis. 2009;199(12):1820–6CrossRefPubMed van Belkum A, Verkaik NJ, de Vogel CP et al. Reclassification of Staphylococcus aureus nasal carriage types. J Infect Dis. 2009;199(12):1820–6CrossRefPubMed
17.
Zurück zum Zitat Schauwvlieghe AFAD, Rijnders BJA, Philips N et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782–792CrossRefPubMed Schauwvlieghe AFAD, Rijnders BJA, Philips N et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782–792CrossRefPubMed
18.
Zurück zum Zitat Kwong JC, Schwartz KL, Campitelli M et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345–353CrossRefPubMed Kwong JC, Schwartz KL, Campitelli M et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345–353CrossRefPubMed
19.
Zurück zum Zitat Modin D, Jørgensen ME, Gislason G et al. Influenza Vaccine in Heart Failure. Circulation. 2019;139(5):575–586CrossRefPubMed Modin D, Jørgensen ME, Gislason G et al. Influenza Vaccine in Heart Failure. Circulation. 2019;139(5):575–586CrossRefPubMed
20.
Zurück zum Zitat Lee KR, Bae JH, Hwang IC et al. Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2017;48(3–4):103–110CrossRef Lee KR, Bae JH, Hwang IC et al. Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2017;48(3–4):103–110CrossRef
21.
Zurück zum Zitat Fukuta H, Goto T, Wakami K et al. The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2019;24(1):109–114CrossRefPubMed Fukuta H, Goto T, Wakami K et al. The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2019;24(1):109–114CrossRefPubMed
22.
Zurück zum Zitat Vasileiou E, Sheikh A, Butler C et al. Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2017;65(8):1388–1395CrossRefPubMedPubMedCentral Vasileiou E, Sheikh A, Butler C et al. Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2017;65(8):1388–1395CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Evans GM, Gaisford WF. Treatment of Pneumonia with 2-(p-aminobenzenesulphonamido) pyridine. Lancet. 1938;232(5992):14–19CrossRef Evans GM, Gaisford WF. Treatment of Pneumonia with 2-(p-aminobenzenesulphonamido) pyridine. Lancet. 1938;232(5992):14–19CrossRef
25.
Zurück zum Zitat Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort. Am J Respir Crit Care Med. 2015;192(5):597–604CrossRefPubMed Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort. Am J Respir Crit Care Med. 2015;192(5):597–604CrossRefPubMed
26.
Zurück zum Zitat Barker WH, Mullooly JP. A study of excess mortality during influenza epidemics in the United States, 1968–1976. Am J Epidemiol. 1982;115(3):479–80CrossRefPubMed Barker WH, Mullooly JP. A study of excess mortality during influenza epidemics in the United States, 1968–1976. Am J Epidemiol. 1982;115(3):479–80CrossRefPubMed
28.
Zurück zum Zitat Schmitzberger, MEDahead Experten Statement 2017 Schmitzberger, MEDahead Experten Statement 2017
29.
Zurück zum Zitat CDC Advisory Committee on Immunization Practices (ACIP) Meeting, Juni 2018 CDC Advisory Committee on Immunization Practices (ACIP) Meeting, Juni 2018
31.
Zurück zum Zitat Gesundheitsministerium, Österreichische Ärztekammer, Östereichische Apothekerkammer Gesundheitsministerium, Österreichische Ärztekammer, Östereichische Apothekerkammer
Metadaten
Titel
Pneumokokken, Pertussis und Influenza
Empfohlene Impfungen bei Lungenkranken
verfasst von
Univ.-Prof. Dr. Florian Thalhammer, DTMH Hamburg
Publikationsdatum
27.08.2019
Verlag
Springer Medizin
Erschienen in
Pneumo News / Ausgabe 5/2019
Print ISSN: 1865-5467
Elektronische ISSN: 2199-3866
DOI
https://doi.org/10.1007/s15033-019-1231-9

Weitere Artikel der Ausgabe 5/2019

Pneumo News 5/2019 Zur Ausgabe